Menthol insulin (Novalis) is the only fast-acting insulin analogue approved by SFDA for use in children over 2 years old with diabetes; while the same fast-acting insulin analogue lysergic insulin is only approved for the treatment of children over 12 years old with diabetes. Menthol insulin and lysergic insulin have similar effects and do not have significant maternal and infant safety issues, so they are gradually being used in the clinic. Among the long-acting insulin analogues, ditropan insulin (Novalis) is approved for the treatment of diabetes in children over 6 years old, and was approved by FDA in 2012 for use in children with type 1 diabetes aged 2 to 5 years old. And glargine insulin is approved for use in children over 12 years of age with diabetes. NPH is still the main application of a basal insulin for gestational diabetes patients; there is less information on glargine insulin, which has a pregnancy use class C and cannot be used during pregnancy; in April 2012, the FDA approved a change in the pregnancy safety classification of Novo Nordisk: Inc.’s Dettol insulin injection from class C to class B. Deferiprone was approved by the State Food and Drug Administration (SFDA) in October 2013 for the treatment of gestational diabetes.